Johnson & Johnson (TSX:JNJ)
Canada · Delayed Price · Currency is CAD | Market Cap | 836.62B +63.7% |
| Revenue (ttm) | 133.68B +7.9% |
| Net Income | 29.19B -3.5% |
| EPS | 11.98 -3.9% |
| Shares Out | n/a |
| PE Ratio | 28.66 |
| Forward PE | 20.51 |
| Dividend | 0.67 (2.13%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 1,500 |
| Open | 32.47 |
| Previous Close | 31.46 |
| Day's Range | 32.44 - 32.58 |
| 52-Week Range | 19.85 - 32.57 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson presents new Imaavy data at EAN 2026 Congress
Johnson & Johnson announced new data across 12 abstracts at the European Academy of Neurology 2026 Congress that offer additional insight into the use of IMAAVY throughout clinically relevant points…
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+ a , anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disea...
Johnson & Johnson price target raised to $270 from $266 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $270 from $266 and keeps a Buy rating on the shares ahead of the company kicking…
Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe
Johnson & Johnson announced the commercial launch of the Dual Energy Thermocool Smarttouch SF Platform in Europe.
Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson today announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe, expanding physician access to a dual-...
3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026
Lowe’s ($LOW), Amcor ($AMCR), and Johnson & Johnson ($JNJ) are the three dividend aristocrat stocks with a Strong Buy rating on Wall Street and payout ratios of more than 50%,…
Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push
Pharma giant Johnson & Johnson ($JNJ) has found a new target for its four-year $55 billion U.S. manufacturing expansion plan launched in March 2025. The company said on Monday that…
Johnson & Johnson invests more than $1B in Jacksonville, Florida
Johnson & Johnson announced an investment of more than $1B in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities. Th...
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billi...
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC...
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
STOCKHOLM, June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study sho...
Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL
Johnson & Johnson is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses. TECNIS PureSee IOL is an extended depth of focus lens designed to support visual...
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is...
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Johnson & Johnson presents first results from ENERGY study
Johnson & Johnson presented the first results from the Phase 2/3 ENERGY study showing that Imaavy produced a statistically significant durable hemoglobin, or Hgb, response with rapid onset of effect…
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
Patients in the IMAAVY 30 mg/kg treatment group a achieved statistically significant durable hemoglobin response b , with mean hemoglobin improvement of at least 1 g/dL as early as Week 1 c More pat...
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
LOS ANGELES--(BUSINESS WIRE)-- #JohnsonJohnson--A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos...
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
Joaquin Duato said finding a cure for certain cancers and turning others into chronic diseases is an achievable target for the coming decade.
Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong growth continues with double-digit gains across key products and new launches in immunology and oncology. TREMFYA and ICOTYDE drive immunology momentum, while RYBREVANT, ERLEADA, and INLEXZO expand oncology opportunities. Neuroscience and cardiovascular assets show robust progress.
Johnson & Johnson to Buy Firefly Bio for $1 Billion
Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker's oncology pipeline.
M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline
Johnson & Johnson stock was a hot topic on Monday after the company announced a $1 billion deal.
Johnson & Johnson to acquire Firefly Bio for $1B in cash
Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink degrader antibody conjugate platform, for $1B in cash. Th...
Johnson & Johnson to buy Firefly Bio for $1 billion
Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline.